FDA clears Foundayo (orforglipron), April 1

FDA approved Eli Lilly's once-daily oral GLP-1 Foundayo for obesity and overweight. The ATTAIN-1 trial showed 12.4% average weight loss (27.3 pounds) at the high dose. LillyDirect began shipping April 6 at $149/month out-of-pocket.